HIV Vaccine Industry Partnership Group
Case study 1: Strengthening industry engagement in HIV vaccine research and development
At AIDS 2022, the Vaccine group hosted a satellite to discuss barriers to industry involvement in HIV vaccine R&D, including recommendations for activating and optimizing industry participation in R&D. Watch the satellite session here and find the report here.
Case study 2: Biomarkers and clinical trial design
In 2022, the group hosted a workshop that explored how biomarkers could be used as surrogate markers of clinical efficacy in counterfactual vaccine trials. To access the workshop report, click here.